ABMD — Abiomed Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $17.18bn
- $16.36bn
- $1.03bn
Annual cashflow statement for Abiomed, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 112 | 259 | 203 | 226 | 137 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 45.7 | 25.6 | 50.5 | 13 | 149 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -18.9 | -38.8 | 8.03 | -17.4 | -30.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 193 | 252 | 315 | 275 | 285 |
| Capital Expenditures | -55.9 | -44 | -44 | -53.4 | -35.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -125 | -72.5 | -81.4 | -170 | -345 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -181 | -116 | -125 | -223 | -381 |
| Financing Cash Flow Items | -20.3 | -71.8 | -41.7 | -11.3 | -18.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -9.14 | -55.8 | -118 | -8.07 | -2.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.94 | 78 | 71.3 | 40.4 | -99.9 |